|
End-of-day quote
Shenzhen S.E.
06/11/2026
|
5-day change | 1st Jan Change | ||
| 46.00 CNY | -3.85% |
|
+0.99% | -22.91% |
Company Valuation: Tibet Duo Rui Pharmaceutical Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Market Cap 1 | 3,113 | 2,587 | 2,134 | 1,419 | 4,711 |
| Change | - | -16.89% | -17.53% | -33.5% | 232.05% |
| Enterprise Value (EV) 1 | 2,522 | 2,183 | 1,831 | 1,554 | 5,038 |
| Change | - | -13.47% | -16.12% | -15.15% | 224.3% |
| P/E | 37.1x | 124x | 111x | -22.7x | -46.3x |
| PBR | 3.93x | 3.44x | 2.76x | 2.1x | 8.2x |
| PEG | -1.2x | -1.6x | -14.43x | 0x | -0.7x |
| Capitalization / Revenue | 5.88x | 6.45x | 6.38x | 5.9x | 30.6x |
| EV / Revenue | 4.76x | 5.44x | 5.48x | 6.46x | 32.7x |
| EV / EBITDA | 33.2x | 133x | 105x | -25.4x | -74x |
| EV / EBIT | 40.4x | 1,204x | -2,455x | -17.7x | -43.1x |
| EV / FCF | 214x | -58.7x | -228x | -18.6x | -35.1x |
| FCF Yield | 0.47% | -1.7% | -0.44% | -5.39% | -2.85% |
| Dividend per Share 2 | 0.625 | - | 0.125 | - | - |
| Rate of return | 1.61% | - | 0.47% | - | - |
| EPS 2 | 1.05 | 0.26 | 0.24 | -0.79 | -1.29 |
| Distribution rate | 59.5% | - | 52.1% | - | - |
| Net sales 1 | 529.6 | 401 | 334.3 | 240.6 | 154.2 |
| EBITDA 1 | 76.06 | 16.37 | 17.37 | -61.1 | -68.07 |
| EBIT 1 | 62.38 | 1.812 | -0.7458 | -87.81 | -116.9 |
| Net income 1 | 68.51 | 20.5 | 18.85 | -62.67 | -102.2 |
| Net Debt 1 | -590.5 | -404.5 | -302.7 | 134.7 | 326.7 |
| Reference price 2 | 38.91 | 32.34 | 26.67 | 17.97 | 59.67 |
| Nbr of stocks (in thousands) | 80,000 | 80,000 | 80,000 | 78,956 | 78,956 |
| Announcement Date | 24/3/22 | 24/4/23 | 17/4/24 | 17/4/25 | 28/4/26 |
1CNY in Million2CNY
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 551M | |
| 39.62x | 13.42x | 28.51x | 0.5% | 1,206B | |
| 40.43x | 6.79x | 19.09x | 1.93% | 665B | |
| 37.45x | 8.51x | 17.57x | 2.38% | 515B | |
| 20.98x | 5.12x | 12.74x | 2.57% | 381B | |
| 97.18x | 5.95x | 25.33x | 2.32% | 362B | |
| 23.18x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.46x | 4.89x | 13.77x | 1.79% | 289B | |
| 23.66x | 7.32x | 13.53x | 2.19% | 249B | |
| -39.95x | 7.29x | 45.82x | 1.98% | 207B | |
| Average | 29.67x | 7.25x | 21.19x | 2.04% | 418.03B | |
| Weighted average by Cap. | 35.62x | 8.55x | 21.86x | 1.73% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 301075 Stock
- Valuation Tibet Duo Rui Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
